RU2017111270A - Фармацевтическая комбинация, содержащая агент анальгетик и спазмолитический агент - Google Patents
Фармацевтическая комбинация, содержащая агент анальгетик и спазмолитический агент Download PDFInfo
- Publication number
- RU2017111270A RU2017111270A RU2017111270A RU2017111270A RU2017111270A RU 2017111270 A RU2017111270 A RU 2017111270A RU 2017111270 A RU2017111270 A RU 2017111270A RU 2017111270 A RU2017111270 A RU 2017111270A RU 2017111270 A RU2017111270 A RU 2017111270A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical combination
- combination according
- antispasmodic
- analgesic agent
- agent
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title 1
- 230000002048 spasmolytic effect Effects 0.000 title 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 13
- 239000000730 antalgic agent Substances 0.000 claims 10
- 230000002921 anti-spasmodic effect Effects 0.000 claims 10
- 229960004384 ketorolac tromethamine Drugs 0.000 claims 7
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 229920000642 polymer Polymers 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 229940124575 antispasmodic agent Drugs 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- 229920005596 polymer binder Polymers 0.000 claims 3
- 239000002491 polymer binding agent Substances 0.000 claims 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 229960004752 ketorolac Drugs 0.000 claims 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical group C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- 229960000281 trometamol Drugs 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical class CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 229960001789 papaverine Drugs 0.000 claims 1
- QNPHCSSJLHAKSA-UHFFFAOYSA-N pargeverine Chemical group C=1C=CC=CC=1C(OCC#C)(C(=O)OCCN(C)C)C1=CC=CC=C1 QNPHCSSJLHAKSA-UHFFFAOYSA-N 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical group C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 1
- 229960002646 scopolamine Drugs 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical group C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims 1
- 229960004045 tolterodine Drugs 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (18)
1. Фармацевтическая комбинация, содержащая анальгезирующий агент и спазмолитический агент, в котором анальгезирующий агент содержит Кеторолака Трометамин и присутствует в указанной композиции в количестве от 5% до 20% по массе и активный спазмолитический агент находится в пропорции от 5% до 20% по массе указанной композиции.
2. Фармацевтическая комбинация по п. 1, в которой анальгезирующий агент Кеторолака Трометамин физически изолирован от спазмолитического средства.
3. Фармацевтическая комбинация по п. 1, в которой спазмолитическим активным компонентом в сочетании с анальгезирующим агентом Кеторолака Трометамином является Гиосцин.
4. Фармацевтическая комбинация по п. 1, в которой спазмолитическим активным компонентом в сочетании с анальгезирующим агентом Кеторолака Трометамином является Паргеверин.
5. Фармацевтическая комбинация по п. 1, в которой спазмолитическим активным компонентом в сочетании с анальгезирующим агентом Кеторолака Трометамином является Толтеродин.
6. Фармацевтическая комбинация по п. 1, в которой спазмолитическим активным компонентом в сочетании с анальгезирующим агентом Кеторолака Трометамином является Мебеверин.
7. Фармацевтическая комбинация по п. 1, в которой спазмолитическим активным компонентом в сочетании с анальгезирующим агентом Кеторолака Трометамином является Папаверин.
8. Фармацевтическая комбинация по п. 1, отличающаяся тем, что анальгезирующий агент Кеторолака Трометамин и спазмолитический агент встречаются в разделенном виде для немедленного освобождения.
9. Фармацевтическая комбинация по п. 1, отличающаяся тем, что анальгезирующий агент Кеторолака Трометамин состоит в настоящей комбинации отдельно и для немедленного высвобождения, в то время как спазмолитическое средство состоит также в раздельной форме, но для котролируемого высвобождения.
10. Фармацевтическая комбинация по п. 1, отличающаяся тем, что она представлена в виде гранул, содержащих активные вещества и имеющих диаметры в диапазоне от 0,2 мм до 1,8 мм, предпочтительно от 0,4 мм до 1,5 мм.
11. Фармацевтическая комбинация по п. 1, отличающаяся тем, что в качестве полимерного связующего используется поливинилпирролидон (PVP K 30).
12. Фармацевтическая комбинация по п. 1, отличающаяся тем, что связующий полимер используется полиэтиленгликоль.
13. Фармацевтическая комбинация по п. 1, отличающаяся тем, что в качестве полимерного связующего используется метилцеллюлоза.
14. Фармацевтическая комбинация по п. 1, отличающаяся тем, что в качестве полимерного связующего используется крахмал и его смеси.
15. Фармацевтическая комбинация по п. 11, отличающаяся тем, что полимерным покрытием для программируемого высвобождения спазмолитического компонента является этилцеллюлоза в различных пропорциях в ацетоновых растворах, спиртовых или водных смесях.
16. Фармацевтическая комбинация по п. 1, отличающаяся тем, что полимерным покрытием для контролируемого высвобождения спазмолитического компонента является гидроксипропилметилцеллюлоза в различных пропорциях в ацетоновых растворах, спиртовых или водных смесях.
17. Фармацевтическая комбинация по п. 1, отличающаяся тем, что полимерным покрытием для контролируемого высвобождения спазмолитического компонента являются акриловые полимеры (Эудрагид L, S, RL, RS, или их комбинации) в различных пропорциях в ацетоновых, спиртовых или водных растворах.
18. Фармацевтическая комбинация по п. 1, отличающаяся тем, что в эту комбинацию включены пластификаторы типа диэтилфалаты, дибутилфалаты, полиэтиленгликоли, триэтилцитраты, триацетин и триглицериды жирных кислот.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| VE118713 | 2013-09-20 | ||
| BRBR1020140233199 | 2014-09-19 | ||
| BR102014023319A BR102014023319A2 (pt) | 2013-09-20 | 2014-09-19 | combinação farmacêutica contendo um agente analgésico e um agente antiespasmódico |
| PCT/BR2015/000146 WO2016041036A1 (pt) | 2014-09-19 | 2015-09-17 | Combinação farmacêutica contendo um agente analgésico e um agente antiespasmódico |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017111270A true RU2017111270A (ru) | 2018-10-19 |
Family
ID=55082767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017111270A RU2017111270A (ru) | 2013-09-20 | 2015-09-17 | Фармацевтическая комбинация, содержащая агент анальгетик и спазмолитический агент |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170281596A1 (ru) |
| EP (1) | EP3195864A4 (ru) |
| AR (1) | AR097675A1 (ru) |
| BR (1) | BR102014023319A2 (ru) |
| RU (1) | RU2017111270A (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024211978A1 (en) * | 2023-04-13 | 2024-10-17 | Aché Laboratórios Farmacêuticos S.A. | Oral pharmaceutical composition, process for the production of granules or an oral pharmaceutical composition, oral pharmaceutical granule, use of the pharmaceutical composition and method for treating inflammatory conditions, pain and/or avoiding the use of perioperative opioid |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014075155A1 (pt) * | 2012-11-14 | 2014-05-22 | Diffucap Chemobras Química E Farmacêutica Ltda | Combinação farmacêutica contendo agente analgésico e agente antiespasmódico |
-
2014
- 2014-09-16 AR ARP140103443A patent/AR097675A1/es unknown
- 2014-09-19 BR BR102014023319A patent/BR102014023319A2/pt not_active Application Discontinuation
-
2015
- 2015-09-17 US US15/512,110 patent/US20170281596A1/en not_active Abandoned
- 2015-09-17 RU RU2017111270A patent/RU2017111270A/ru not_active Application Discontinuation
- 2015-09-17 EP EP15842123.0A patent/EP3195864A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AR097675A1 (es) | 2016-04-06 |
| EP3195864A1 (en) | 2017-07-26 |
| BR102014023319A2 (pt) | 2015-12-15 |
| EP3195864A4 (en) | 2018-05-16 |
| US20170281596A1 (en) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2409069B2 (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| MX377553B (es) | Composicion farmaceutica estable y metodos de uso de la misma. | |
| HRP20201043T1 (hr) | Spojevi 4-amino-imidazokinolina | |
| RU2014101227A (ru) | Композиция покрытия, подходящая для фармацевтических или нутрицевтических лекарственных форм | |
| JP2012236837A5 (ru) | ||
| NZ710792A (en) | Tofacitinib oral sustained release dosage forms | |
| JP2013014622A5 (ru) | ||
| JP2014218522A5 (ru) | ||
| JP2013509429A5 (ru) | ||
| JP2014129360A5 (ru) | ||
| JP2015078230A5 (ru) | ||
| RU2014149010A (ru) | Форма многослойного покрытия фармацевтической композиции для перорального применения, содержащей омега-3 жирную кислоту или ее алкиловый сложный эфир, а также лекарственное средство на основе статина | |
| JP2012525817A5 (ru) | ||
| BR112013003946A2 (pt) | uso de diidromiricetina para a preparação de um medicamento a ser administrado a receptores gabaa que serão, são e/ou foram expostos a etanol e uso de diidromiricetina para a preparação de um medicamento a ser adminstrado a recptores gabaa antes, durante e/ou depois da exposição ao etanol . | |
| FR2961507B1 (fr) | Procede de preparation d'acroleine a partir de glycerol ou de glycerine | |
| JP2014503479A5 (ja) | アリピプラゾール組成物 | |
| RU2015143891A (ru) | Фармацевтические составы тамсулозина или его солей | |
| JP2017505336A5 (ru) | ||
| RU2017111270A (ru) | Фармацевтическая комбинация, содержащая агент анальгетик и спазмолитический агент | |
| WO2013017910A8 (en) | Extended release pharmaceutical compositions containing paliperidone | |
| RU2016115985A (ru) | Лактоферрин для лечения ibd, вызванного бактериальной инвазией | |
| RU2012151315A (ru) | Энтеросолюбильная таблетка | |
| CL2014000509A1 (es) | Co-cristales que comprenden ciprodinil y ditianon; proceso para preparar los co-cristales; composicion para la proteccion de cultivos que comprende dichos co-cristales; uso para combatir hobgos fitopatógenos. | |
| EA201890744A1 (ru) | Фармацевтическая композиция, содержащая 8-[(3r)-3-амино-1-пиперидинил]-7-(2-бутин-1-ил)-3,7-дигидро-3-метил-1-[(4-метил-2-хиназолинил)метил]-1h-пурин-2,6-дион или его фармацевтически приемлемую соль | |
| RU2016103087A (ru) | Комбинированная композиция, содержащая метформин замедленного высвобождения и ингибитор HMG-CoA-редуктазы немедленного высвобождения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20180918 |